These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 12211437)

  • 21. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
    Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies.
    Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ
    J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonate effects and the bone remodeling transient.
    Heaney RP; Yates AJ; Santora AC
    J Bone Miner Res; 1997 Aug; 12(8):1143-51. PubMed ID: 9258743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ; Im JA; Kim SH
    Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weekly administration of alendronate: rationale and plan for clinical assessment.
    Bone HG; Adami S; Rizzoli R; Favus M; Ross PD; Santora A; Prahalada S; Daifotis A; Orloff J; Yates J
    Clin Ther; 2000 Jan; 22(1):15-28. PubMed ID: 10688387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on alendronate for osteoporosis: once-weekly dosing.
    Schnitzer TJ
    Expert Opin Pharmacother; 2001 Sep; 2(9):1461-72. PubMed ID: 11585024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.
    Hernandez CJ; Beaupré GS; Marcus R; Carter DR
    Bone; 2001 Dec; 29(6):511-6. PubMed ID: 11728920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-weekly treatment for osteoporosis.
    Stone M
    Hosp Med; 2002 Apr; 63(4):230-2. PubMed ID: 11995275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once weekly alendronate.
    Sambrook P
    Drugs Today (Barc); 2003 May; 39(5):339-46. PubMed ID: 12861347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response.
    Calvo-Gallego JL; Pivonka P; Ruiz-Lozano R; Martínez-Reina J
    Front Bioeng Biotechnol; 2022; 10():940620. PubMed ID: 36061434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective dosage and administration schedule of oral alendronate for non-nociceptive symptoms in rats with chronic constriction injury.
    Im S; Lim SH; Lee JI; Ko YJ; Park JH; Hong BY; Park GY
    J Korean Med Sci; 2010 Jun; 25(6):938-44. PubMed ID: 20514318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats.
    Stepensky D; Golomb G; Hoffman A
    J Pharm Sci; 2002 Feb; 91(2):508-16. PubMed ID: 11835209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weekly dose of osteoporosis drug.
    Casale JA
    Am J Nurs; 2002 May; 102(5):13. PubMed ID: 12006843
    [No Abstract]   [Full Text] [Related]  

  • 39. In silico experiments of bone remodeling explore metabolic diseases and their drug treatment.
    Kameo Y; Miya Y; Hayashi M; Nakashima T; Adachi T
    Sci Adv; 2020 Mar; 6(10):eaax0938. PubMed ID: 32181336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of adding an MSC-specific ligand to alendronate.
    Bonekey Rep; 2012; 1():72. PubMed ID: 23951465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.